Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

13
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
13
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

14
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor,...
14
Hyperthyroidism I: Introduction01:25

Hyperthyroidism I: Introduction

11
Hyperthyroidism is a type of thyrotoxicosis characterized by the thyroid gland's overproduction of the thyroid hormones triiodothyronine (T3) and thyroxine (T4). This hormone excess increases the basal metabolic rate and enhances sensitivity to catecholamines.DiagnosisDiagnosis is based on clinical features and biochemical testing. It typically shows suppressed thyroid-stimulating hormone (TSH) levels below 0.4 mIU/L, with elevated free T3 and/or T4. Additional tests, including thyroid...
11
Goiter01:27

Goiter

21
Goiter refers to an abnormal enlargement of the thyroid gland that may appear as a diffuse goiter (uniform enlargement) or nodular (single or multiple nodules). Functionally, it is classified as nontoxic (normal/low hormone levels) or toxic (excess hormone production).PathophysiologyDiffuse thyroid enlargement typically results from prolonged stimulation by thyroid-stimulating hormone (TSH) or TSH-like agents, commonly seen in hypothyroidism or iodine deficiency. In contrast, in hyperthyroid...
21
Hyperthyroidism II: Pathophysiology01:27

Hyperthyroidism II: Pathophysiology

10
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH...
10
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

7.0K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<italic>MKRN3</italic> Variants in Central Precocious Puberty as an Example of the Complexity to Classify Missense Variants in Imprinted Genes as Pathogenic.

Hormone research in paediatrics·2026
Same author

EndoCompass Project: Research Roadmap for Thyroid Endocrinology.

Hormone research in paediatrics·2025
Same author

EndoCompass project: research roadmap for thyroid endocrinology.

European journal of endocrinology·2025
Same author

Digenic Inheritance Mode in Congenital Hypothyroidism Due to Thyroid Dysgenesis: HYPOTYGEN Translational Cohort Study.

The Journal of clinical endocrinology and metabolism·2025
Same author

Early-onset anorexia nervosa: a scoping review and management guidelines.

Journal of eating disorders·2024
Same author

Systematic review of thyroid function in NKX2-1-related disorders: Treatment and follow-up.

PloS one·2024

Related Experiment Video

Updated: Apr 23, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.7K

Graves' disease in children.

Juliane Léger1

  • 1Université Paris Diderot, Sorbonne Paris Cité, Service d'Endocrinologie et Diabétologie Pédiatrique et Centre de Référence des Maladies Endocriniennes Rares de la Croissance, Hôpital Robert-Debré, AP-HP, et Institut National de la Santé et de la Recherche Médicale, UMR 1141, Paris, France.

Endocrine Development
|September 19, 2014
PubMed
Summary
This summary is machine-generated.

Graves' disease in children often relapses after initial treatment. Prolonged therapy or alternative options like radioactive iodine may be needed, with ongoing research aiming to improve remission rates and long-term outcomes.

More Related Videos

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis
05:41

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

Published on: February 9, 2024

1.3K
Author Spotlight: Accurately Assessing Thyroid Hormone-Driven Motor Alterations in Mouse
04:05

Author Spotlight: Accurately Assessing Thyroid Hormone-Driven Motor Alterations in Mouse

Published on: October 6, 2023

850

Related Experiment Videos

Last Updated: Apr 23, 2026

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model
04:39

Generation of a Mouse Spontaneous Autoimmune Thyroiditis Model

Published on: March 17, 2023

2.7K
Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis
05:41

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

Published on: February 9, 2024

1.3K
Author Spotlight: Accurately Assessing Thyroid Hormone-Driven Motor Alterations in Mouse
04:05

Author Spotlight: Accurately Assessing Thyroid Hormone-Driven Motor Alterations in Mouse

Published on: October 6, 2023

850

Area of Science:

  • Pediatric Endocrinology
  • Autoimmune Diseases
  • Thyroid Disorders

Background:

  • Graves' disease is the leading cause of hyperthyroidism in children, increasing with age and peaking in adolescence.
  • Antithyroid drugs (ATDs) are the primary treatment, though relapse rates are high in pediatric patients.

Purpose of the Study:

  • To review current management strategies for pediatric Graves' disease.
  • To identify factors influencing treatment success and relapse.
  • To highlight areas for future research in optimizing patient outcomes.

Main Methods:

  • Review of existing literature on pediatric Graves' disease management.
  • Analysis of treatment efficacy, relapse rates, and predictive factors for ATD therapy.
  • Discussion of alternative treatment modalities and future research directions.

Main Results:

  • Remission rates after initial ATD treatment are low (around 30%), increasing to 50% with prolonged therapy.
  • Factors like severe hyperthyroidism at diagnosis and absence of other autoimmune conditions predict relapse.
  • Alternative treatments are considered for relapsed, non-compliant, or intolerant patients.

Conclusions:

  • Optimizing ATD treatment duration and exploring predictive factors are crucial for managing pediatric Graves' disease.
  • Further research should focus on improving drug compliance, understanding long-term effects of treatments, and identifying predictors of remission.
  • Enhanced understanding of disease pathophysiology may lead to better remission rates and patient management.